Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels

Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H1032-9. doi: 10.1152/ajpheart.01004.2002. Epub 2003 May 1.

Abstract

To examine the receptor specificity and the mechanism of opioid peptide-induced protection, we examined freshly isolated adult rabbit cardiomyocytes subjected to simulated ischemia. Cell death as a function of time was assessed by trypan blue permeability. Dynorphin B (DynB) and Met5-enkephalin (ME) limitation of cell death (expressed as area under the curve) was sensitive to blockade by naltrindole (NTI, a delta-selective antagonist) and 5'-guanidinyl-17-(cyclopropylmethyl)-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan (GNTI dihydrochloride, a kappa-selective antagonist): 85.7 +/- 2.7 and 142.9 +/- 2.7 with DynB and DynB + NTI, respectively (P < 0.001), 94.1 +/- 4.2 and 164.5 +/- 7.3 with DynB and DynB + GNTI, respectively (P < 0.001), 111.9 +/- 7.0 and 192.1 +/- 6.4 with ME and ME + NTI, respectively (P < 0.001), and 120.2 +/- 4.3 and 170.0 +/- 3.3 with ME and ME + GNTI, respectively (P < 0.001). Blockade of ATP-sensitive K+ channels eliminated DynB- and ME-induced protection: 189.6 +/- 5.4 and 139.0 +/- 5.4 for control and ME, respectively (P < 0.001), and 210 +/- 5.9 and 195 +/- 6.1 for 5-HD and ME + 5-HD, respectively (P < 0.001); 136.0 +/- 5.7 and 63.4 +/- 5.4 for control and ME, respectively (P < 0.001), and 144.6 +/- 4.5 and 114.6 +/- 7.7 for HMR-1098 and ME + HMR-1098, respectively (P < 0.01); 189.6 +/- 5.4 and 139.0 +/- 5.4 for control and ME, respectively (P < 0.001), and 210 +/- 5.9 and 195 +/- 6.1 for 5-HD and ME + 5-HD, respectively (P < 0.001); and 136.0 +/- 5.7 and 63.4 +/- 5.4 for control and ME, respectively (P < 0.001), and 144.6 +/- 4.5 and 114.6 +/- 7.7 for HMR-1098 and ME + HMR-1098, respectively (P < 0.01). We conclude that opioid peptide-induced cardioprotection is mediated by delta- and kappa-receptors and involves sarcolemmal and mitochondrial ATP-sensitive K+ channels.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Benzamides / pharmacology
  • Cardiotonic Agents / pharmacology
  • Dose-Response Relationship, Drug
  • Dynorphins / pharmacology*
  • Endorphins / pharmacology*
  • Enkephalin, Methionine / pharmacology*
  • Guanidines
  • Ischemic Preconditioning, Myocardial
  • Male
  • Mitochondria / metabolism
  • Morphinans
  • Myocardial Ischemia / metabolism*
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Potassium Channels / metabolism*
  • Rabbits
  • Receptors, Opioid, delta / metabolism*
  • Receptors, Opioid, kappa / metabolism*
  • Sarcolemma / metabolism

Substances

  • 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan
  • Benzamides
  • Cardiotonic Agents
  • Endorphins
  • Guanidines
  • Morphinans
  • Narcotic Antagonists
  • Potassium Channels
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Enkephalin, Methionine
  • Naltrexone
  • Dynorphins
  • rimorphin
  • Adenosine Triphosphate
  • HMR 1098
  • naltrindole